Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Injectable anti-HIV therapies could see strong growth

By Brian Buntz | February 22, 2021

HIV

Photo by Miguel Á. Padriñán from Pexels

The market for injectable anti-HIV therapeutics will be worth $28 billion by 2029, according to projections from the analyst and consulting firm GlobalData.

GlobalData valued the broader HIV therapeutics market at $22.9 billion in 2019 across the U.S., France, Germany, Italy, Spain, U.K. and Japan.

While the overall market is growing at a low single-digit rate, injectable therapies will likely see more brisk growth, GlobalData projects.

To date, the majority of HIV therapies are orally delivered antiretroviral drugs, although a handful of injectable drugs have been introduced over the years.

Future injectable anti-HIV therapies could be administered less frequently than oral drugs. One early injectable anti-HIV therapy, Fuzeon (enfuvirtide) from Roche (OTCMKTS:RHHBY), is administered multiple times per day, posing a challenge for adherence. FDA approved the drug in 2003.

GlobalData projects that sales of injectable therapies for HIV will exceed $1.8 billion by 2029.

The European Medicines Agency recommended the first long-acting injectable antiretroviral therapy for HIV last year. The recommendation related to a combination of the drugs Rekambys (rilpivirine) and Vocabria (cabotegravir), which Johnson & Johnson’s (NYSE:JNJ) Janssen unit developed. The FDA approved the injectable formulation of rilpivirine and cabotegravir in January.

Other injectable anti-HIV therapies will be available by 2029, said Magdalene Crabbe, a senior GlobalData analyst, in a statement. Crabb pointed to leronlimab from CytoDyn (OTCMKTS:CYDY) and lenacapavir from Gilead Sciences (NSDQ:GILD) as examples of drugs likely to hit E.U. and U.S. market in coming years.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Becton Dickinson GSL Solutions
Becton Dickinson acquires smart medication device maker GSL Solutions
COVID-19 vaccine
How COVID-19 sidelined top vaccine manufacturers  
Pharmaceutical environment
Pharma’s been slow to adopt Industry 4.0 — but that could change
Johnson & Johnson Merck COVID-19 vaccine
Biden announces partnership for Merck to make J&J’s COVID-19 vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards